The AbbVie story
What drives AbbVie, what its price assumes and what could change the story, written from its own filings.
- Growth has accelerated. Revenue rose 10.4% over the last twelve months through June 2026, compared with annual growth of 1.8% over the last three years.
- Immunology gets another investment. AbbVie completed its approximately $10.9 billion Apogee acquisition on September 3, 2026, adding clinical programs for inflammatory diseases.
- Guidance remains conditional. AbbVie’s 2026 adjusted diluted EPS guidance of $13.76 to $13.96 excludes acquired research and milestone expenses incurred beyond the quarter to September 2026.
